First trial for young kids with rare neurological disease
NCT ID NCT06054893
Summary
This study aims to find the right dose and check the safety of the drug omaveloxolone (SKYCLARYS®) in children and teenagers aged 2 to 15 with Friedreich's ataxia. The drug is already approved for people 16 and older, but researchers need to understand how younger bodies process it. The study will involve about 35 participants and will track their health for up to 240 weeks to monitor for side effects and see how the drug works over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.